ERBB2 and breast cancer: Currently, there are two clinical trials testing nintedanib combined with paclitaxel (NCT01484080, phase I/II) and docetaxel (NCT01658462, phase II) in early and in metastatic or locally recurrent HER2-negative breast cancer, respectively.